Dyadic International (DYAI) AI Stock Analysis

• Market Cap: $28.29M
• Dividend Yield: N/A
• Average Volume (3M): 48.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: 20.58%
• EPS Growth: 15.90%
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 30,090,660
• 10 Day Avg. Volume: 82,726
• 30 Day Avg. Volume: 48,594
• PEG Ratio: 0.13
• Price to Book (P/B): 3.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.32
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 2.38
• Enterprise Value/Gross Profit: 12.24
• Enterprise Value/Ebitda: -1.30
• 1Y Price Target: $6.00
• Price Target Upside: 538.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: ―

Dyadic International's overall score reflects significant financial challenges, notably ongoing losses and negative cash flows. While strategic partnerships and revenue growth are positive, they are offset by high leverage and operational inefficiencies. The stock's technical indicators suggest weak momentum, and its valuation remains unattractive due to unprofitability. The earnings call provides some optimism about future growth, but near-term challenges persist.

Dyadic International Business Overview & Revenue Model

Company Description

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

How the Company Makes Money

Dyadic International generates revenue through licensing its C1 gene expression technology to pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and royalties based on the commercial success of products developed using the C1 platform. The company also engages in research and development collaborations, where it provides its expertise and technology in exchange for funding. Additionally, Dyadic may generate revenue through the sale of its proprietary enzymes and other bio-based products developed using its platform.

Dyadic International Financial Statement Overview

Summary

Dyadic International faces significant financial challenges, including ongoing losses and negative cash flows. Despite some revenue growth, the company's high leverage and operational inefficiencies pose risks. However, maintaining liquidity through cash reserves is a positive aspect.

Income Statement

Dyadic International has shown some revenue growth over the years, with a 20.6% increase from 2023 to 2024. However, the company has consistently reported negative net income, leading to negative net profit margins. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.

Balance Sheet

The company's debt-to-equity ratio has increased significantly in 2024, indicating higher leverage and potential financial risk. The equity ratio has decreased over the years, reflecting a lower proportion of equity financing. However, the company maintains a reasonable amount of cash and short-term investments, providing some liquidity cushion.

Cash Flow

Operating cash flows have been negative, reflecting challenges in generating cash from operations. Free cash flow has also remained negative, though there was a notable decrease in the cash outflow in 2024 compared to previous years. The operating cash flow to net income ratio indicates a gap between reported earnings and cash generation, which may concern investors.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.55M	3.50M	2.90M	2.93M	2.40M	1.60M
Gross Profit	2.38M	2.30M	922.96K	807.11K	459.39K	176.99K
EBITDA	-8.47M	-5.38M	-8.19M	-10.07M	-13.07M	-10.19M
Net Income	-5.83M	-5.81M	-6.80M	-9.37M	-12.92M	-9.33M
Balance Sheet
Total Assets	7.89M	9.93M	8.22M	13.71M	21.30M	30.07M
Cash, Cash Equivalents and Short-Term Investments	7.35M	9.26M	7.26M	12.64M	20.26M	29.09M
Total Debt	5.07M	5.07M	136.93K	0.00	0.00	0.00
Total Liabilities	6.97M	7.46M	2.34M	2.63M	2.91M	1.63M
Stockholders Equity	923.61K	2.47M	5.88M	11.09M	18.39M	28.45M
Cash Flow
Free Cash Flow	-4.81M	-3.97M	-6.73M	-8.08M	-11.28M	-6.57M
Operating Cash Flow	-4.81M	-3.97M	-6.73M	-8.08M	-11.28M	-6.57M
Investing Cash Flow	-739.24K	-1.88M	7.45M	-2.37M	5.22M	22.12M
Financing Cash Flow	48.50K	5.85M	0.00	543.59K	1.23M	255.47K

Dyadic International Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.94
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DYAI, the sentiment is Negative. The current price of 0.94 is below the 20-day moving average (MA) of 0.97, below the 50-day MA of 1.04, and below the 200-day MA of 1.31, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 41.66 is Neutral, neither overbought nor oversold. The STOCH value of 24.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DYAI.

Dyadic International Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	66 Neutral	€1.74B	33.92	8.73%	1.75%	7.10%	103.68%
SPRO	48 Neutral	$162.14M	10.83	-107.28%	―	-71.68%	-397.61%
DYAI	46 Neutral	$28.29M	―	-214.26%	―	20.58%	15.90%
BRNS	44 Neutral	$38.16M	―	-45.40%	―	4413.19%	10.56%
IBIO	42 Neutral	$12.00M	―	-90.83%	―	650.00%	89.72%
CELU	41 Neutral	$48.62M	―	-232.51%	―	138.11%	76.60%
ANTX	34 Underperform	$32.59M	―	-49.32%	―	―	38.98%

Dyadic International Corporate Events

Dyadic International Director Arindam Bose Announces Retirement

On April 28, 2025, Arindam Bose announced his decision to retire as a director of Dyadic International, Inc., effective at the company’s annual meeting on June 20, 2025. His retirement is not due to any disagreements with the company regarding its operations, policies, or practices.

Spark’s Take on DYAI Stock

According to Spark, TipRanks’ AI Analyst, DYAI is a Neutral.

Dyadic International’s overall score reflects significant financial challenges, notably ongoing losses and negative cash flows. While strategic partnerships and revenue growth are positive, they are offset by high leverage and operational inefficiencies. The stock’s technical indicators suggest weak momentum, and its valuation remains unattractive due to unprofitability. The earnings call provides some optimism about future growth, but near-term challenges persist.

To see Spark’s full report on DYAI stock, click here.

Dyadic International Secures $4.5M for Vaccine Development

On March 20, 2025, Dyadic International announced a $4.5 million funding award from CEPI to accelerate the development of protein-based vaccines using its C1 fungus technology. The initiative aims to reduce vaccine development timelines significantly, potentially enabling vaccines to enter Phase 1 trials in just 35 days compared to the traditional four to six months. This approach could also lower production costs and increase accessibility, particularly in regions with less established manufacturing infrastructure, aligning with the global 100 Days Mission to expedite vaccine readiness against pandemic threats.